Royalty Pharma
RPRX
RPRX
231 hedge funds and large institutions have $9.59B invested in Royalty Pharma in 2021 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 92 increasing their positions, 78 reducing their positions, and 38 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less first-time investments, than exits
New positions opened: | Existing positions closed:
1.6% less ownership
Funds ownership: 63.75% → 62.15% (-1.6%)
2% less funds holding
Funds holding: 235 → 231 (-4)
7% less capital invested
Capital invested by funds: $10.3B → $9.59B (-$675M)
Holders
231
Holding in Top 10
11
Calls
$45.5M
Puts
$17.1M
Top Buyers
| 1 | +$475M | |
| 2 | +$235M | |
| 3 | +$205M | |
| 4 |
BlackRock
New York
|
+$187M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$78.8M |
Top Sellers
| 1 | -$432M | |
| 2 | -$180M | |
| 3 | -$72.2M | |
| 4 |
VCG
Vantage Consulting Group
Virginia Beach,
Virginia
|
-$52M |
| 5 |
Amundi
Paris,
France
|
-$51.9M |